163 related articles for article (PubMed ID: 3348609)
1. A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria.
Fernandes PB; Chu DT; Swanson RN; Ramer NR; Hanson CW; Bower RR; Stamm JM; Hardy DJ
Antimicrob Agents Chemother; 1988 Jan; 32(1):27-32. PubMed ID: 3348609
[TBL] [Abstract][Full Text] [Related]
2. E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens.
Guinea J; Gargallo-Viola D; Robert M; Tudela E; Xicota MA; Garcia J; Esteve M; Coll R; Pares M; Roser R
Antimicrob Agents Chemother; 1995 Feb; 39(2):413-21. PubMed ID: 7726507
[TBL] [Abstract][Full Text] [Related]
3. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.
Hardy DJ; Swanson RN; Hensey DM; Ramer NR; Bower RR; Hanson CW; Chu DT; Fernandes PB
Antimicrob Agents Chemother; 1987 Nov; 31(11):1768-74. PubMed ID: 3435123
[TBL] [Abstract][Full Text] [Related]
4. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
King A; Bethune L; Phillips I
J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
6. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
King A; Shannon K; Slegg J; Phillips I
J Antimicrob Chemother; 1986 Aug; 18(2):163-9. PubMed ID: 3463557
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.
Clement JJ; Tanaka SK; Alder J; Vojtko C; Beyer J; Hensey D; Ramer N; McDaniel D; Chu DT
Antimicrob Agents Chemother; 1994 May; 38(5):1071-8. PubMed ID: 8067740
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of WIN 57273 compared to the activity of other fluoroquinolones and two beta-lactam antibiotics.
Chin NX; Neu HC
J Antimicrob Chemother; 1991 Jun; 27(6):781-91. PubMed ID: 1657856
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
[TBL] [Abstract][Full Text] [Related]
10. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.
Chin NX; Neu HC
Antimicrob Agents Chemother; 1984 Mar; 25(3):319-26. PubMed ID: 6232895
[TBL] [Abstract][Full Text] [Related]
11. In-vitro and in-vivo activities of T-3262, a new pyridone carboxylic acid.
Takahata M; Otsuki M; Nishino T
J Antimicrob Chemother; 1988 Aug; 22(2):143-54. PubMed ID: 3182417
[TBL] [Abstract][Full Text] [Related]
12. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
King A; Phillips I
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
[TBL] [Abstract][Full Text] [Related]
13. [Susceptibility of bacteria isolated from clinical material to ciprofloxacin].
Namysł E; Galiński J; Szponar M; Piechowicz L
Med Dosw Mikrobiol; 1995; 47(1-2):5-9. PubMed ID: 8523970
[TBL] [Abstract][Full Text] [Related]
14. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
[TBL] [Abstract][Full Text] [Related]
15. In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent.
Cohen MA; Huband MD; Mailloux GB; Yoder SL; Roland GE; Domagala JM; Heifetz CL
Antimicrob Agents Chemother; 1991 Jan; 35(1):141-6. PubMed ID: 2014970
[TBL] [Abstract][Full Text] [Related]
16. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
Goldstein EJ; Citron DM; Hudspeth M; Hunt Gerardo S; Merriam CV
J Antimicrob Chemother; 1998 Mar; 41(3):391-6. PubMed ID: 9578167
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of CP-74,667. A new fluoroquinolone compared with other quinolones.
Gu JW; Fang W; Chin NX; Neu HC
Diagn Microbiol Infect Dis; 1992; 15(7):613-20. PubMed ID: 1330421
[TBL] [Abstract][Full Text] [Related]
18. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM
Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615
[TBL] [Abstract][Full Text] [Related]
19. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Oct; 38(10):2471-6. PubMed ID: 7840591
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of the new fluoroquinolone CP-99,219.
Neu HC; Chin NX
Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
